GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intercept Pharmaceuticals Inc (FRA:I4P) » Definitions » Policy Acquisition Expense

Intercept Pharmaceuticals (FRA:I4P) Policy Acquisition Expense


View and export this data going back to 2012. Start your Free Trial

What is Intercept Pharmaceuticals Policy Acquisition Expense?

Policy Acquisition Expense only applies to insurance companies.


Intercept Pharmaceuticals (FRA:I4P) Business Description

Traded in Other Exchanges
N/A
Address
305 Madison Avenue, Morristown, NJ, USA, 07960
Intercept Pharmaceuticals Inc is a biotech company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.